Metabolism in Kidney Disease

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 591

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicine and Surgery, University of Enna “Kore”, 94100 Enna, Italy
Interests: acid-bases disorders; chronic kidney diseases; electrolytes; epidemiology; hemodialysis; hypertension; nephrology

E-Mail Website
Guest Editor
Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, AOU “G. Martino”, 98100 Messina, Italy
Interests: CKD; electrolytes; epidemiology; pregnancy

E-Mail Website
Guest Editor
Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, A.O.U. “G.Martino”, University of Messina, 98125 Messina, Italy
Interests: CKD; dialysis electrolytes; glomerulonephritis; C3GN; renal biopsy; renal immunopathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metabolism changes in CKD patients interest electrolyte dysregulation, hormone disorders, bone-mineral diseases, microelement anomalies, as well as different drug dynamics. Furthermore, these developments are different from CKD patients rather than dialysis patients. This special issue aims to evaluate all the changes in metabolism in conservative CKD patients and dialysis patients and compare them.

In this Special Issue, original research articles and reviews are welcome, as well as brief reports and systematic reviews. Research areas may include (but are not limited to) the following: electrolyte dysregulation, hormone disorders, bone-mineral diseases, microelement anomalies, as well as different drug dynamics. Furthermore, papers about nursing topics will be well accepted, to the scope of promoting nursing research that we consider much relevant in the clinical practice.

We look forward to receiving your contributions.

Dr. Vincenzo Calabrese
Dr. Elisa Longhitano
Prof. Dr. Domenico Santoro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • CKD
  • dialysis
  • electrolytes
  • metabolism
  • inflammation
  • survey

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 740 KiB  
Article
Plasma Dickkopf-1 Levels Are Associated with Chronic Kidney Disease
by Yu-Hsuan Li, Yu-Cheng Cheng, Junyi Wu and I-Te Lee
Metabolites 2025, 15(5), 300; https://doi.org/10.3390/metabo15050300 - 30 Apr 2025
Viewed by 109
Abstract
Background: Wnt/β-catenin signaling is important in the development and repair of the kidney. Dickkopf-1 (DKK-1) is characterized as an inhibitor of the Wnt/β-catenin signaling pathway. Purpose: We examined the relationship between plasma DKK-1 levels and the risk of chronic kidney disease (CKD). Methods: [...] Read more.
Background: Wnt/β-catenin signaling is important in the development and repair of the kidney. Dickkopf-1 (DKK-1) is characterized as an inhibitor of the Wnt/β-catenin signaling pathway. Purpose: We examined the relationship between plasma DKK-1 levels and the risk of chronic kidney disease (CKD). Methods: In this cross-sectional study, patients without known diabetes mellitus who were admitted for coronary angiography due to angina were enrolled. Fasting blood samples were collected at a predetermined outpatient visit. Results: Among 373 enrolled patients, 62 (16.6%) were in the CKD group, and 311 (83.4%) were in the nonCKD group. Plasma DKK-1 levels were significantly higher in the CKD group than in the nonCKD group (697.2 ± 174.7 vs. 589.0 ± 193.3 pg/mL; p < 0.001). Plasma DKK-1 levels were inversely correlated with the eGFR (Pearson’s correlation coefficient = −0.265; p < 0.001). On the basis of multivariable logistic regression analyses, patients in the highest DKK-1 quartile had a significantly greater risk of CKD (OR = 4.188; 95% CI: 1.564, 11.212; p = 0.004) than did those in the lowest DKK-1 quartile. Conclusions: Plasma DKK-1 levels are associated with the risk of CKD in patients with angina. Further studies investigating the underlying mechanisms involved in the relationship between DKK-1 and CKD are warranted. Full article
(This article belongs to the Special Issue Metabolism in Kidney Disease)
Show Figures

Figure 1

Other

Jump to: Research

16 pages, 1396 KiB  
Systematic Review
Adiponectin and All-Cause Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis
by Hyun Suk Yang, Soo-Nyung Kim, Jung-Hoon Ro and Mina Hur
Metabolites 2025, 15(4), 230; https://doi.org/10.3390/metabo15040230 - 27 Mar 2025
Viewed by 255
Abstract
Background/Objectives: Elevated levels of adiponectin in chronic kidney disease (CKD) have been paradoxically associated with increased mortality. This meta-analysis aimed to evaluate the association between circulating adiponectin levels and all-cause mortality in patients with CKD, in total and various subgroups. Methods: [...] Read more.
Background/Objectives: Elevated levels of adiponectin in chronic kidney disease (CKD) have been paradoxically associated with increased mortality. This meta-analysis aimed to evaluate the association between circulating adiponectin levels and all-cause mortality in patients with CKD, in total and various subgroups. Methods: We systematically searched PubMed, Embase, and Cochrane Library from their inception to December 2024 for studies examining baseline adiponectin levels and observed mortality outcomes in patients with CKD. Studies were included if they evaluated CKD stages 2–5 patients, measured baseline circulating adiponectin levels, and reported hazard ratios (HRs) for all-cause mortality. We excluded non-original research, studies of acute conditions, normal kidney function, kidney transplantation, and those using log-transformed or standardized HRs. HRs with a 95% confidence interval (CI) for all-cause mortality risk per 1 µg/mL increase in adiponectin were extracted and analyzed using the Comprehensive Meta-Analysis Version 4. Study quality was assessed using the Newcastle–Ottawa Scale. Results: Twelve studies with 2523 subjects were included. The pooled unadjusted HR was 1.003 (95% CI: 0.981–1.025) using a random-effects model (I2 = 79%). Subgroup analyses demonstrated increased mortality risk with elevated adiponectin levels in non-Asia (HR 1.021 [95% CI: 1.006–1.037], p = 0.006), studies with female proportion <47% (HR 1.021 [95% CI: 1.009–1.033], p < 0.001), and studies with body mass index ≥25 kg/m2 (HR 1.023 [95% CI: 1.008–1.038], p = 0.003). In contrast, higher adiponectin levels were associated with decreased mortality risk in the peritoneal dialysis group (HR 0.956 [95% CI: 0.934–0.979], p < 0.001) and female proportion ≥47% group (HR 0.929 [95% CI: 0.874–0.988], p = 0.019). Discussion/Conclusions: This meta-analysis revealed that elevated adiponectin levels have varying associations with the risk of all-cause mortality across CKD patient subgroups. These findings suggest that the prognostic value of adiponectin levels in CKD may be modulated by demographic and clinical factors. Limitations include poor generalizability with underrepresentation of early-stage CKD. This research received no external funding and was not registered. Full article
(This article belongs to the Special Issue Metabolism in Kidney Disease)
Show Figures

Figure 1

Back to TopTop